[go: up one dir, main page]

MXPA04004019A - Derivados de pirimido?4,5-b?indol. - Google Patents

Derivados de pirimido?4,5-b?indol.

Info

Publication number
MXPA04004019A
MXPA04004019A MXPA04004019A MXPA04004019A MXPA04004019A MX PA04004019 A MXPA04004019 A MX PA04004019A MX PA04004019 A MXPA04004019 A MX PA04004019A MX PA04004019 A MXPA04004019 A MX PA04004019A MX PA04004019 A MXPA04004019 A MX PA04004019A
Authority
MX
Mexico
Prior art keywords
diseases
pyrimido
disease
present
mkk7
Prior art date
Application number
MXPA04004019A
Other languages
English (en)
Inventor
Lowinger Timothy
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001334662A external-priority patent/JP2003137886A/ja
Priority claimed from GB0214544A external-priority patent/GB2390090A/en
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MXPA04004019A publication Critical patent/MXPA04004019A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a pirimido?4,5-b?indoles que son de utilidad como un ingrediente activo de preparaciones farmaceuticas. Los primido?4,5-b?indoles de la presente invencion poseen actividad inhidora de MKK7 y MKK4 y pueden usarse para la profilaxis y el tratamiento de enfermedades asociadas a la actividad de MKK7 y MKK4.Enfermedades de ese tipo incluyen, trastornos y enfermedades inflamatorias e inmunorreguladores y enfermedades tales como asma, dermatitis atopica, rinitis, rinitis alergica, enfermedades alergicas, EPOC, choque septicemico, artritis, enfermedades de las articulaciones y lesiones de miocardio, asi como patologias autoinmunes tales como artritis reumatoide, enfermedad de Grave y aterosclerosis.Los compuestos de la presente invencion son tambien de utilidad para el tratamiento de isquemia, lesion miocardica, hipertension pulmonar, insuficiencia renal, corea de Huntington e hipertrofia cardiaca, asi como trastornos neurodegenerativos tales como la enfermedad de Parkinson, enfermedad de Alzheimer e isquemia focal.
MXPA04004019A 2001-10-31 2002-10-29 Derivados de pirimido?4,5-b?indol. MXPA04004019A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001334662A JP2003137886A (ja) 2001-10-31 2001-10-31 ピリミド［４，５−ｂ］インドール
GB0214544A GB2390090A (en) 2002-06-24 2002-06-24 Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles
PCT/EP2002/012057 WO2003037898A1 (en) 2001-10-31 2002-10-29 Pyrimido [4,5-b] indole derivatives

Publications (1)

Publication Number Publication Date
MXPA04004019A true MXPA04004019A (es) 2004-07-08

Family

ID=26247088

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004019A MXPA04004019A (es) 2001-10-31 2002-10-29 Derivados de pirimido?4,5-b?indol.

Country Status (5)

Country Link
EP (1) EP1442039A1 (es)
JP (1) JP2005515173A (es)
CA (1) CA2464934A1 (es)
MX (1) MXPA04004019A (es)
WO (1) WO2003037898A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2390090A (en) * 2002-06-24 2003-12-31 Bayer Ag Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles
AU2003300522A1 (en) * 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
EP1888588A2 (en) * 2005-04-28 2008-02-20 SuperGen, Inc. Protein kinase inhibitors
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US7960400B2 (en) * 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
US7982035B2 (en) * 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
PT2247558T (pt) 2008-02-14 2022-03-21 Lilly Co Eli Novos agentes de imagiologia para deteção de disfunção neurológica
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
AU2011281015B2 (en) 2010-07-23 2015-09-24 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
PH12013501800A1 (en) 2011-03-15 2013-10-14 L Livermore Nat Security Llc Tricyclic gyrase inhibitors
EP2776417B1 (en) 2011-11-09 2018-10-31 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
EP2806875B1 (en) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
DK2807165T3 (da) * 2012-01-27 2019-07-15 Univ Montreal Pyrimido[4,5-b]indol-derivater og anvendelse deraf i ekspansionen af hæmatopoietiske stamceller
EP3210980B1 (en) 2012-05-15 2024-04-03 Cancer Research Technology Ltd Process for manufacturing 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)- 2-pyridyl]amino]pyrazine-2-carbonitrile
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN104016985B (zh) * 2013-03-01 2017-11-03 华东理工大学 一种吡唑并嘧啶化合物及其用途
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
ES2788977T3 (es) * 2014-04-22 2020-10-23 Univ Montreal Compuestos y uso de los mismos en la expansión de células madre hematopoyéticas y/o células progenitoras hematopoyéticas
WO2016067009A1 (en) * 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
CN107922926B (zh) 2015-06-05 2021-09-10 赫马魁北克公司 培养和/或使造血干细胞分化为祖细胞的方法及其用途
RU2625316C1 (ru) * 2016-04-13 2017-07-13 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) 2-АМИНОЗАМЕЩЕННЫЕ 6-МЕТОКСИ-4-ТРИФТОРМЕТИЛ-9Н-ПИРИМИДО[4,5b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ПРЕДШЕСТВЕННИКИ
WO2018017153A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
CN107353288B (zh) * 2017-06-23 2019-10-18 吉林大学 4-乙胺(2-羧基)-9H-嘧啶并[4,5-b]吲哚及其制备方法
ES3000465T3 (en) 2018-01-31 2025-02-28 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US12011460B2 (en) 2018-02-20 2024-06-18 Universite De Montreal Expansion of NK and DC cells in vivo mediating immune response
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7365393B2 (ja) 2018-07-16 2023-10-19 ヘパリジェニックス ゲーエムベーハー 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤
US11485734B2 (en) 2018-10-02 2022-11-01 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)
AU2020320001B2 (en) * 2019-07-29 2025-08-21 Heparegenix Gmbh Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021106230A1 (ja) 2019-11-29 2021-06-03 大鵬薬品工業株式会社 新規なフェノール化合物又はその塩
JP7639008B2 (ja) 2020-01-15 2025-03-04 ヘパリジェニックス ゲーエムベーハー 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤
WO2024233776A1 (en) * 2023-05-09 2024-11-14 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12d mutant
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors
US12466840B2 (en) 2023-10-20 2025-11-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
KR19980702716A (ko) * 1995-03-02 1998-08-05 웰츠로렌스티 피리미도[4,5-비]인돌
ES2193424T3 (es) * 1997-01-08 2003-11-01 Upjohn Co Aminas triciclicas farmaceuticamente activas.

Also Published As

Publication number Publication date
CA2464934A1 (en) 2003-05-08
WO2003037898A1 (en) 2003-05-08
JP2005515173A (ja) 2005-05-26
EP1442039A1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
MXPA04004019A (es) Derivados de pirimido?4,5-b?indol.
ECSP055768A (es) Derivados de azol-pirimidina condensados
IL185289A0 (en) Substituted pyrido (2,3-d) pyrimidine derivatives useful as medicines for the treatment of autoimmune disorders
WO2006069805A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2009003669A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
PL1673092T3 (pl) Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu
WO2007061763A3 (en) Indole orexin receptor antagonists
NO20085326L (no) Pyrido[3,2-e]pyraziner, deres anvendelser som inhibitorer av fosfodiesterase 10, og fremgangsmater for fremstilling av dem
NO20070467L (no) Pyrrolopyrimidin og pyrrolopyridinderivater substituert med tetrahydropyridin som CRF antagonister
WO2005063766A3 (en) Bicyclic heterocyclic p-38 kinase inhibitors
WO2011051342A8 (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
HK1044545A1 (zh) 贝他分泌酶组合物及其方法
ATE187447T1 (de) 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
UA90707C2 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
CY1107264T1 (el) Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
WO2007019234A3 (en) Aminoethane sulfonamide orexin receptor antagonists
WO2002056832A3 (en) Methods to treat autoimmune and inflammatory conditions
MX2007000046A (es) Compuestos, composiciones y metodos de imidazolo relacionados para su uso.
CA2534303A1 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
WO2006090289A8 (en) Compounds for reducing aggregation of amyloid beta-peptide
DOP2003000724A (es) Derivados de azol-pirimidina condensados
HK40107402A (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto